A compound of formula (Ig-2): wherein R 15 is cyclopropyl; Y 2 is H, halogen, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C 3-8 cycloalkyl-C 0-4 alkyl or (R 2)(R 3)N-, wherein R 2 and R 3 are each independently selected from the group consisting of H, C 1-6 alkyl, C 1-6 alkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C 3-8 cycloalkyl-C 0-4 alkyl, heterocycloalkyl and heterocycloalkyl-C 1-4 alkyl; or R 2 and R 3 taken together with the nitrogen atom to which they are attached form a three to eight-membered ring having from 0-2 additional heteroatoms as ring members selected from N, O or S; wherein Y 2 is optionally substituted with from one to three groups independently selected from R e; Q is selected from H, F, Cl or CH 3; R 11 is C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or R e; the subscript m is an integer from 0 to 3; the subscript n is an integer from 1 to 5; and R e is selected from the group consisting of halogen, -CH=CH 2, -CN, -OH, -NH 2, -NO 2, -C OH, -C OH, -C NH 2, -C NH 2, -S 2 NH 2, -NHC NH 2, -NHC NH 2, -NHS 2 NH 2, -C NH 2, -OR f, -SR f, -OC R f, -OC R f, -C R f, -C R f, -C OR f, -C OR f, -S R f, -S 2 R f, -C NHR f, -C NHR f, -C NR f R f, -C NR f R f, -S 2 NHR f, -S 2 NR f R f, -C NHR f, -C NR f R f, -NHC R f, -NHC R f, -NR f C R f, -NR f C R f, -NHS 2 R f, -NR f S 2 R f, -NHC NHR f, -NHC NHR f, -NR f C NH 2, -NR f C NH 2, -NR f C NHR f, -NR f C NHR f, -NHC NR f R f, -NHC NR f R f, -NR f C NR f R f, -NR f C NR f R f, -NHS 2 NHR f, -NR f S 2 NH 2, -NR f S 2 NHR f, -NHS 2 NR f R f, -NR f S 2 NR f R f, -NHR f, -NR f R f and R f, wherein R f is C 1-6 alkyl or aryl; wherein cycloalkyl by itself or as part of another substituent, refers to saturated or unsaturated, non-aromatic monocyclic, bicyclic or tricyclic carbon ring systems of 3-8 ring members; and heterocycloalkyl refers to a saturated or unsaturated non-aromatic cycloalkyl group that contains from one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized, the remaining ring atoms being C, where one or two C atoms may optionally be replaced by a carbonyl; or a pharmaceutically acceptable salt, a hydrate, a solvate, a stereoisomer, or a mixture of stereoisomers thereof. wherein R 15 is cyclopropyl; Y 2 is H, halogen, CN, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 haloalkyl, C 1-6 haloalkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C 3-8 cycloalkyl-C 0-4 alkyl or (R 2)(R 3)N-, wherein R 2 and R 3 are each independently selected from the group consisting of H, C 1-6 alkyl, C 1-6 alkoxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, C 3-8 cycloalkyl-C 0-4 alkyl, heterocycloalkyl and heterocycloalkyl-C 1-4 alkyl; or R 2 and R 3 taken together with the nitrogen atom to which they are attached form a three to eight-membered ring having from 0-2 additional heteroatoms as ring members selected from N, O or S; wherein Y 2 is optionally substituted with from one to three groups independently selected from R e; Q is selected from H, F, Cl or CH 3; R 11 is C 1-6 alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl or R e; the subscript m is an integer from 0 to 3; the subscript n is an integer from 1 to 5; and R e is selected from the group consisting of halogen, -CH=CH 2, -CN, -OH, -NH 2, -NO 2, -C OH, -C OH, -C NH 2, -C NH 2, -S 2 NH 2, -NHC NH 2, -NHC NH 2, -NHS 2 NH 2, -C NH 2, -OR f, -SR f, -OC R f, -OC R f, -C R f, -C R f, -C OR f, -C OR f, -S R f, -S 2 R f, -C NHR f, -C NHR f, -C NR f R f, -C NR f R f, -S 2 NHR f, -S 2 NR f R f, -C NHR f, -C NR f R f, -NHC R f, -NHC R f, -NR f C R f, -NR f C R f, -NHS 2 R f, -NR f S 2 R f, -NHC NHR f, -NHC NHR f, -NR f C NH 2, -NR f C NH 2, -NR f C NHR f, -NR f C NHR f, -NHC NR f R f, -NHC NR f R f, -NR f C NR f R f, -NR f C NR f R f, -NHS 2 NHR f, -NR f S 2 NH 2, -NR f S 2 NHR f, -NHS 2 NR f R f, -NR f S 2 NR f R f, -NHR f, -NR f R f and R f, wherein R f is C 1-6 alkyl or aryl; wherein cycloalkyl by itself or as part of another substituent, refers to saturated or unsaturated, non-aromatic monocyclic, bicyclic or tricyclic carbon ring systems of 3-8 ring members; and heterocycloalkyl refers to a saturated or unsaturated non-aromatic cycloalkyl group that contains from one to five heteroatoms selected from N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized, the remaining ring atoms being C, where one or two C atoms may optionally be replaced by a carbonyl; or a pharmaceutically acceptable salt, a hydrate, a solvate, a stereoisomer, or a mixture of stereoisomers thereof.